BioPorto Announces Submission of Response to FDA Additional Information Letter

2 years ago

June 29, 2023News release BioPorto Announces Submission of Response to FDA Additional Information Letter COPENHAGEN, DENMARK and BOSTON, MA, June…

EssilorLuxottica and Jimmy Choo announce a ten-year licensing agreement

2 years ago

EssilorLuxottica and Jimmy Chooannounce a ten-year licensing agreement Charenton-le-Pont, France and London, UK (June 29, 2023 – 8:00 am CEST) –…

Junshi Biosciences Announces Initiation of Phase 3 Study of Tifcemalimab plus Toripalimab for Treatment of Limited-stage Small Cell Lung Cancer

2 years ago

SHANGHAI, China, June 29, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a…

Press Release: Vaccines R&D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal disease

2 years ago

  Vaccines Investor EventVaccines R&D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal disease Sanofi reaffirms ambition to…

Santhera Publishes Timeline of the Reverse Share Split

2 years ago

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL…

CorMedix Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Pre-Funded Warrants

2 years ago

BERKELEY HEIGHTS, N.J., June 28, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and…

Rakovina Therapeutics Announces Results from 2023 Annual General Meeting

2 years ago

VANCOUVER, British Columbia, June 28, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company”), a biopharmaceutical company committed…

Ipsen announces positive outcome of FDA Advisory Committee on investigational palovarotene for fibrodysplasia ossificans progressiva

2 years ago

Advisory committee voted 10 for and 4 against that evidence from the Phase III MOVE study show palovarotene is an…

Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02

2 years ago

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today…

Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02

2 years ago

REYKJAVIK, Iceland, June 28, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture…